Localized or Locally Advanced Prostate Cancer
Conditions
Brief summary
This study is a multi-centre, prospective observational study. The study plans to enrol 500 patients with localized or locally advanced prostate cancer who are eligible and intended to be prescribed Zoladex® (goserelin acetate implant) 10.8 mg or Zoladex® (goserelin acetate implant) 3.6 mg as monotherapy or in combination with androgen blockade (CAB) at 50 clinical sites in China. The effectiveness and safety data will be collected at baseline and each visit within 26 weeks after treatment of Zoladex®.
Detailed description
Androgen Deprivation Therapy (ADT) is a standard treatment for locally advanced or metastatic prostate cancer. It is also increasingly used in patients with high-risk localized prostate cancer or in patients with prostate-specific antigen (PSA) relapse after local therapy. The luteinizing hormone-releasing hormone (LHRH) agonists, such as goserelin acetate(Zoladex®), have provided an effective and reversible means of suppressing androgen level. Zoladex® was originally formulated as a 3.6mg depot injection. Goserelin acetate 10.8-mg depot, given once every 3 months, is pharmacodynamically equivalent to 3 consecutive monthly injections of the goserelin acetate 3.6-mg depot, offers a more convenient and cost-effective dosing regimen for patients. Goserelin acetate 10.8-mg depot has been available in China since 2012. However, data on the effectiveness and safety of the long-acting depot of Zoladex® (goserelin acetate depot) 10.8mg specifically in a Chinese population is limited. A real-world observational study is proposed to establish the effectiveness and safety profile of Zoladex ® 10.8mg in Chinese patients with localized or locally advanced prostate cancer.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
1. Ability to provide informed consent, complete all study assessments and have complete medical record; 2. Male aged 18 years and over; 3. Diagnosis of localized or locally advanced prostate cancer requiring immediate hormonal therapy; 4. Being prescribed Zoladex ® (goserelin acetate implant) 10.8 mg or Zoladex ® (goserelin acetate implant) 3.6 mg in accordance with the terms of marketing authorization as monotherapy or in combination with androgen blockade (CAB); 5. More than 26 weeks' life expectancy;
Exclusion criteria
1. Patients who are planned to receive radiation therapy; 2. Patients with hypersensitivity to LHRH, its analogues, or any components of goserelin depot; 3. Previous or concurrent hormonal therapy including surgical castration, androgen blockers, oestrogen therapy, or other LHRH agonists.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PSA level | each visit within 26 weeks during treatment | Change from baseline in PSA level at each visit within 26 weeks during treatment |
| Serum Testosterone | each visit within 26 weeks during treatment | Change from baseline in the serum Testosterone at each visit within 26 weeks during treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with serum Testosterone less than 50 ng/ml | each visit within 26 weeks during treatment | Number of patients with serum Testosterone less than 50 ng/ml at each visit within 26 weeks during treatment |
| Incidence of Adverse Events (AEs) | each visit within 26 weeks during treatment | Incidence of Adverse Events (AEs) |
| Incidence of AESI (cardiovascular related AE, sexual related AE) | each visit within 26 weeks during treatment | Incidence of AESI (cardiovascular related AE, sexual related AE) |
| Mean serum Testosterone level | each visit within 26 weeks during treatment | Mean serum Testosterone level at baseline and each visit within 26 weeks during treatment |
| Incidence of AEs leading to treatment discontinuation | each visit within 26 weeks during treatment | Incidence of AEs leading to treatment discontinuation |
| Proportion of patients with serum Testosterone less than 50 ng/ml | each visit within 26 weeks during treatment | Proportion of patients with serum Testosterone less than 50 ng/ml at each visit within 26 weeks during treatment |
| Incidence of Serious Adverse Events (SAEs) | each visit within 26 weeks during treatment | Incidence of Serious Adverse Events (SAEs) |
| Incidence of Adverse Drug Reactions (ADRs) | each visit within 26 weeks during treatment | Incidence of Adverse Drug Reactions (ADRs) |
| Mean serum PSA level | each visit within 26 weeks during treatment | Mean serum PSA level at baseline and each visit within 26 weeks during treatment |
Countries
China
Outcome results
None listed